Enlivex Therapeutics Ltd (ENLV) — Cash Flow-to-Debt Ratio
Enlivex Therapeutics Ltd (ENLV) has a Cash Flow-to-Debt Ratio of -0.66x as of September 2025, meaning its operating cash flow of ILA-2.30 Million could theoretically repay -1% of its total liabilities (ILA3.46 Million) in one year. Explore Enlivex Therapeutics Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enlivex Therapeutics Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Enlivex Therapeutics Ltd across 13 annual periods. Also explore Enlivex Therapeutics Ltd total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Enlivex Therapeutics Ltd (2012–2024)
Year-by-year debt coverage analysis for Enlivex Therapeutics Ltd. For market capitalisation and broader financial context, see Enlivex Therapeutics Ltd (ENLV) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.17x | ILA-13.01 Million | ILA4.10 Million | ▲ +9.0% |
| 2023 | -3.49x | ILA-23.52 Million | ILA6.75 Million | ▼ -57.2% |
| 2022 | -2.22x | ILA-23.95 Million | ILA10.80 Million | ▼ -27.8% |
| 2021 | -1.74x | ILA-17.54 Million | ILA10.11 Million | ▲ +23.2% |
| 2020 | -2.26x | ILA-11.01 Million | ILA4.87 Million | ▼ -101.5% |
| 2019 | -1.12x | ILA-7.04 Million | ILA6.28 Million | ▲ +52.9% |
| 2018 | -2.38x | ILA-3.16 Million | ILA1.33 Million | ▲ +82.8% |
| 2017 | -13.81x | ILA-6.35 Million | ILA460.00K | ▼ -72.2% |
| 2016 | -8.02x | ILA-15.49 Million | ILA1.93 Million | ▼ -56.4% |
| 2015 | -5.13x | ILA-13.25 Million | ILA2.58 Million | ▼ -165.1% |
| 2014 | -1.93x | ILA-4.41 Million | ILA2.28 Million | ▲ +70.7% |
| 2013 | -6.60x | ILA-865.00K | ILA131.00K | ▼ -259.0% |
| 2012 | -1.84x | ILA-149.00K | ILA81.00K | — |